Tazemetostat is an orally bioavailable, S-adenosyl-L-methionine–competitive inhibitor of enhancer of zeste homolog 2 in Polycomb Repressive Complex 2, providing sub-20 nM blockade of histone H3-lysine-27 trimethylation and triggering apoptosis in SMARCB1-deleted cancers.
Usually ships within 24 hours.